Poxel S.A. Stock
€0.76
Your prediction
Poxel S.A. Stock
Pros and Cons of Poxel S.A. in the next few years
Pros
Cons
Performance of Poxel S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Poxel S.A. | -5.110% | 72.688% | 106.427% | 35.185% | 627.355% | -58.651% | -89.544% |
| Valneva SE | -0.290% | -4.438% | -5.746% | -35.092% | 29.268% | -75.014% | -27.569% |
| Nanobiotix | -1.360% | 8.542% | 24.074% | -42.196% | 25.170% | -19.629% | -57.051% |
| Transgene S.A. | 40.120% | 1.176% | 11.688% | -44.605% | 0.438% | -71.032% | -51.206% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Looking at the financial statements of Poxel, a biotechnology and medical research company, it is evident that the firm has experienced a challenging financial performance in recent years. A quick assessment of the company's financials reveals a decrease in total assets and an increase in total liabilities. The company's net income has also been in the negative territory. Nonetheless, Poxel operates in a high-risk, high-reward industry which could justify the massive investments in research and development and ultimately impact its financials.
Investments in Research and Development: Poxel consistently invests a significant amount in research and development, which is crucial for a biotechnology company. This commitment to R&D could potentially lead to valuable discoveries and breakthrough innovations in the future, translating into substantial revenue and profits for the company.
Cash Reserves: The company maintains a considerable cash balance, which is beneficial for a research-based company. This cash can be used to fund ongoing operations, acquisitions, and investments in cutting-edge research, offering a buffer against potential financial challenges.
Comments
News
New Clinical and Scientific Data on TWYMEEG® to be Presented at the 68th Annual Meeting of the Japan Diabetes Society
Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025
Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic